Navigation Links
Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
Date:9/13/2007

BIRMINGHAM, Ala., Sept. 13 /PRNewswire-USNewswire/ -- Southern Research Institute today announced that it has licensed the rights to 4'-Thio-Ara-C, also known as SR9025, to Virium Pharmaceuticals, Inc. To date, six of Southern Research's anti-cancer drugs have received FDA approval and are on the market. Six others, including 4'-Thio-Ara-C, are in late stage preclinical testing or in early clinical trials.

(Photo: http://www.newscom.com/cgi-bin/prnh/20070913/DCTH022 )

"Southern Research's agreement with Virium helps bring our work one step closer to the patients we hope to help. This is the first anti-cancer compound to be licensed after the completion of early clinical trials and we are eager to see it move through the pipeline," said John A. "Jack" Secrist, III, Ph.D., president and CEO of Southern Research. "We appreciate being able to work with a company when the success of our drug candidate is important to the success of the company."

The 4'-Thio-Ara-C compound, now registered to Virium as VP700, has shown activity against certain types of leukemia and autoimmune diseases. It is a third generation, novel nucleoside analog that has already completed two phase I trials.

"Southern Research's prestigious cancer program and international track record are well known and respected in the industry. The opportunity to work with a compound designed and developed by researchers at Southern Research is very exciting," said James Pachence, Ph.D., Virium Pharmaceuticals president and CEO. "Our strategy is to focus on targets that play key roles in diseases, and which can potentially be exploited in multiple indications beyond oncology. In addition to VP700, we are currently developing a portfolio of chemistry-driven HDAC inhibitors for cancer."

Southern Research will receive cash and stock in Virium, and will hold seats on the Virium Pharmaceuticals Scientific Advisory Board and the Board of Directors. The technical seat will be filled by Dr. Secrist and the Board seat (non-voting) will be filled by Dr. Nancy M. Gray, vice president of Corporate Development at Southern Research.

ABOUT SOUTHERN RESEARCH

Southern Research is a not-for-profit organization that conducts scientific research at facilities in Alabama, Maryland, Missouri and North Carolina. Southern Research provides contract and basic research in the fields of preclinical drug discovery and development, advanced engineering, and environmental and energy-related research. For more information, see http://www.SouthernResearch.org.

ABOUT VIRIUM PHARMACEUTICALS

Virium Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics with an initial focus on cancer. Virium has its lead cancer product, VP101, in clinical trials in the United States. VP101 is an HDAC inhibitor being developed in collaboration with the National Cancer Institute of the NIH. For more information, visit http://www.viriumpharma.com.

Media Contact:

Rhonda Jung Risa Goldman Burgess

Southern Research Institute Schwartz Communications

205-581-2317 781-684-0770

Jung@southernresearch.org southern@schwartz-pr.com


'/>"/>
SOURCE Southern Research Institute
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Minneapolis company sets sights on southern Wisconsin
2. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
3. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
4. Control Your siRNA Research
5. Getting Started with MicroRNA Research
6. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
7. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
8. Research Organics
9. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
10. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
11. Research Tools for Analysis of ZAP-70
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. ... a free webinar on Performing Quality Investigations: Getting to Root Cause. ... at no charge. , Incomplete investigations are still a major concern to the ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):